Patents Assigned to Vitrisa Therapeutics, Inc.
  • STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN-8
    Publication number: 20210230599
    Abstract: The application discloses methods and compositions for inhibiting functions associated with Interleukin-8 (IL8). The methods and compositions may involve the use of aptamers for binding to IL8 and preventing or reducing association of IL8 with CXCR1, CXCR2, or both. The methods and compositions may include one or more aptamers that bind to an N-terminal domain of IL8. The methods and compositions may include one or more aptamers that bind to a hydrophobic pocket of IL8. The methods and compositions may include one or more aptamers that bind to an N-loop of IL8. The methods and compositions may include one or more aptamers that bind to a GAG binding site of IL8. The application further provides anti-IL8 aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-IL8 aptamers may have a stem-loop secondary structure.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 29, 2021
    Applicant: VITRISA THERAPEUTICS, INC.
    Inventors: Carl ERICKSON, Christopher P. RUSCONI, Arijit BHOWMICK, Matthew LEVY, Matthew WALKER, Kevin G. MCLURE
  • Stem-loop compositions and methods for inhibiting factor D
    Patent number: 10428330
    Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: October 1, 2019
    Assignees: Vitrisa Therapeutics, Inc., Albert Einstein College of Medicine
    Inventors: Carl Erickson, Christopher P. Rusconi, Kevin G. McLure, Matthew Levy, Arijit Bhowmick
  • Compositions with improved intravitreal half-life and uses thereof
    Patent number: 10308943
    Abstract: Provided herein are compositions and methods for the treatment of retinal diseases. The compositions and methods include a therapeutic agent conjugated to a vitreous component binding moiety. The vitreous component binding moiety may be an aptamer or a small molecule that binds to a structural component of the vitreous humor (e.g., hyaluronic acid, collagen or vitronectin).
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 4, 2019
    Assignee: Vitrisa Therapeutics, Inc.
    Inventors: Carl Erickson, Christopher P. Rusconi, Kevin G. McLure, Renta Hutabarat
  • Compositions and methods for inhibiting Factor D
    Patent number: 10174325
    Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 8, 2019
    Assignee: Vitrisa Therapeutics, Inc.
    Inventors: Carl Erickson, Christopher P. Rusconi, Kevin G. McLure